Cancers, Vol. 16, Pages 1538: From Diabetes to Oncology: Glucagon-like Peptide-1 (GLP-1) Receptor Agonist & rsquo;s Dual Role in Prostate Cancer

Cancers, Vol. 16, Pages 1538: From Diabetes to Oncology: Glucagon-like Peptide-1 (GLP-1) Receptor Agonist’s Dual Role in Prostate Cancer Cancers doi: 10.3390/cancers16081538 Authors: Abdulrahman Alhajahjeh Raad Al-Faouri Hisham F. Bahmad Taima’ Bader Ryan W. Dobbs Ahmed A. Abdulelah Wassim Abou-Kheir Elai Davicioni David I. Lee Mohammed Shahait Glucagon-like peptide-1 (GLP-1), an incretin hormone renowned for its role in post-meal blood sugar regulation and glucose-dependent insulin secretion, has gained attention as a novel treatment for diabetes through GLP-1 receptor agonists (GLP-1-RA). Despite their efficacy, concerns have been raised regarding the potential associations between GLP-1-RA and certain malignancies, including medullary thyroid cancer. However, evidence of its association with prostate cancer (PCa) remains inconclusive. This review delves into the intricate relationship between GLP-1-RA and PCa, exploring the mechanisms through which GLP-1-Rs may impact PCa cells. We discuss the potential pathways involving cAMP, ERK, AMPK, mTOR, and P27. Furthermore, we underscore the imperative for additional research to elucidate the impact of GLP-1-RA treatment on PCa progression, patient outcomes, and potential interactions with existing therapies. Translational studies and clinical trials are crucial for a comprehensive understanding of the role of GLP-1-RA in PCa management.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research